NCT06920901View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Asthma
Interventions
DRUG

APG777

APG777 subcutaneous injection

DRUG

Placebo

Matching placebo subcutaneous injection

Trial Locations (11)

15241

Investigational Site, Pittsburgh

19140

Investigational Site, Philadelphia

61761

Investigational Site, Normal

66160

Investigational Site, Kansas City

73034

Investigational Site, Edmond

90505

Investigational Site, Torrance

90808

Investigational Site, Long Beach

92037

Investigational Site, La Jolla

95117

Investigational Site, San Jose

BD9 6RJ

Investigational Site, Bradford

M23 9QZ

Investigational Site, Manchester

Sponsors
All Listed Sponsors
lead

Apogee Therapeutics, Inc.

INDUSTRY